



## HOOKIPA Pharma to Present at SVB Leerink 9th Annual Global Healthcare Conference

February 18, 2020

NEW YORK and VIENNA, Austria, Feb. 18, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will present and host one-on-one meetings at the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25 - 27, 2020 in New York:

- **Presentation:** Tuesday, **February 25, 2020 at 10:00 a.m. ET**, Lotte New York Palace, **Room Kennedy I**

A live audio webcast of the presentation held at the SVB Leerink Healthcare Conference will be available within the Investors & Media section of HOOKIPA's website at <https://ir.hookipapharma.com/events>. An archived replay will be accessible for 30 days following the event.

### About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, VaxWave<sup>®\*</sup>, a replication-deficient viral vector, and TheraT<sup>®\*</sup>, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8<sup>+</sup> T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration to augment and refresh immune responses. TheraT<sup>®</sup> has the potential to induce CD8<sup>+</sup> T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA's "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.

HOOKIPA's VaxWave<sup>®</sup>-based prophylactic Cytomegalovirus vaccine candidate is currently in a Phase 2 clinical trial in patients awaiting kidney transplantation from living Cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The TheraT<sup>®</sup> based lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND submission is intended for the first half of 2020.

Find out more about HOOKIPA online at [www.hookipapharma.com](http://www.hookipapharma.com).

\*Registered in Europe; Pending in the US.

For further information, please contact:

#### Media

Nina Waibel  
Senior Director - Communications  
[Nina.Waibel@HookipaPharma.com](mailto:Nina.Waibel@HookipaPharma.com)

#### Investors

Matt Beck  
Executive Director - Investor Relations  
[Matthew.Beck@HookipaPharma.com](mailto:Matthew.Beck@HookipaPharma.com)

#### Media enquiries

Ashley Tapp  
Instinctif Partners  
[Hookipa@Instinctif.com](mailto:Hookipa@Instinctif.com)  
+44 (0)20 7457 2020